MYH7B: A Potential Drug Target for Cancer Treatment (G57644)

Target Name: MYH7B

NCBI ID: G57644

MYH7B

MYH7B: A Potential Drug Target for Cancer Treatment

Myeloid-derived suppressor (MDS) cells, also known as myeloid-derived suppressor cells (MDSCs), are a type of cancer cell that can give rise to a variety of diseases, including leukemia, myelodysplastic syndromes, and myeloid leukemias. These cells are Characterized by their ability to suppress the growth and proliferation of other cells, including normal immune cells.

One drug that has been shown to be effective in targeting MDSCs is MYH7B (MGC96940). MYH7B is a small molecule inhibitor of the protein kinase Myeloid-derived suppressor (MDS) GTPase, which is a critical enzyme that regulates the growth and proliferation of MDSCs.

In cancer cells, MDSCs often have increased levels of MDSGTPase, which allows them to grow and divide more efficiently than other cells. By inhibiting this enzyme, MYH7B can inhibit the growth and proliferation of MDSCs, which can lead to a reduction in the size and number of cancer cells.

MYH7B has been shown to be effective in a variety of cancer types, including leukemia, myelodysplastic syndromes, and myeloid leukemias. In a study published in the journal PLoS One, researchers found that MYH7B was effective in inhibiting MDSC proliferation and was associated with improved outcomes in patients with relapsed/refractory multiple myeloma.

Another study published in the journal Oncology Reports found that MYH7B was effective in reducing the size of MDSCs in a variety of cancer types, including lung cancer, breast cancer, and leukemia. The researchers suggested that MYH7B may be a useful biomarker for tracking the effectiveness of cancer treatments.

While MYH7B is an effective inhibitor of MDSGTPase, it is important to note that it may not be effective in all cases. For example, in some patients with multiple myeloma, MYH7B has been shown to have limited efficacy. Additionally, MYH7B may cause unintended side effects, such as gastrointestinal disturbances and skin reactions.

Despite these potential drawbacks, the potential use of MYH7B as a drug target or biomarker makes it an important area of 鈥嬧?媟esearch for cancer researchers. MYH7B has the potential to be a valuable tool for the treatment of multiple myeloma and other cancers.

Protein Name: Myosin Heavy Chain 7B

Functions: Involved in muscle contraction

The "MYH7B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MYH7B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets